New Brunswick-based Johnson & Johnson has announced plans to invest more than $55 billion in manufacturing, research and development (R&D), and technology across the United States over the next four years—a 25 percent increase from the previous period. The move builds on the company’s heightened U.S. investments following the 2017 Tax Cuts & Jobs Act.
“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, chairman and CEO of Johnson & Johnson. “Our increased U.S. investment begins with the groundbreaking of a high-tech facility in North Carolina, which will add U.S.-based jobs and manufacture cutting-edge medicines for patients worldwide.”
Beyond the new North Carolina facility, Johnson & Johnson’s expanded U.S. investment will include the construction of three additional advanced manufacturing facilities and the expansion of several existing sites within its Innovative Medicine and MedTech businesses. These projects are expected to generate high-paying, high-technology jobs. The company is also committing significant resources to expanding its research and development infrastructure to support advancements in oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.
Additionally, Johnson & Johnson is increasing its investment in technology to speed up drug discovery and development, enhance workforce training, and improve overall business operations. With these commitments, the company’s U.S. economic impact, which already exceeds $100 billion per year, is expected to grow substantially over the next four years.
